Rise Kester, APRN
Acute Care · Kingfisher, OKNPI 1063637130
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations.
Across 120 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$283
- AstraZeneca$246
- Novo Nordisk$235
- Otsuka America Pharmaceutical, Inc.$211
- Xeris Pharmaceuticals, Inc.$171
- AbbVie$164
- plus $993 from 21 others
What the payments were for
- Food & beverage$2,25398%
- Education$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 13 | $283 |
| AstraZeneca(2 entities) | 14 | $246 |
| Novo Nordisk | 14 | $235 |
| Otsuka America Pharmaceutical, Inc. | 10 | $211 |
| Xeris Pharmaceuticals, Inc. | 8 | $171 |
| AbbVie | 9 | $164 |
| Lilly USA, LLC | 10 | $155 |
| Dexcom, Inc. | 7 | $154 |
| Exact Sciences | 7 | $123 |
| Lundbeck LLC | 3 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| Abbott | 3 | $66 |
| Sumitomo Pharma America, Inc. | 3 | $63 |
| Currax Pharmaceuticals LLC | 2 | $50 |
| Pfizer | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $22 |
| Genentech USA, Inc. | 1 | $22 |
| Edwards Lifesciences | 1 | $21 |
| Merck | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Amgen | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Inogen, Inc. | 1 | $9 |
| Phathom Pharmaceuticals, Inc. | 1 | $9 |
How this compares
$2,303 in reported general payments places this provider in the 75th percentile of 266 acute care providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 147 | $154,755 |
| EliquisApixaban | 155 | $110,980 |
| FarxigaDapagliflozin Propanediol | 140 | $110,797 |
| OzempicSemaglutide | 87 | $92,349 |
| JardianceEmpagliflozin | 128 | $92,124 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $45,423 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $40,712 |
| RexultiBrexpiprazole | 29 | $38,356 |
| Tresiba Flextouch U-100Insulin Degludec | 77 | $36,362 |
| GemtesaVibegron | 64 | $35,769 |
| CreonLipase/Protease/Amylase | 14 | $33,294 |
| VraylarCariprazine Hcl | 20 | $30,080 |
| JanuviaSitagliptin Phosphate | 22 | $29,729 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $24,271 |
| TrulicityDulaglutide | 22 | $24,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $155 | $178,867169 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $246 | $135,067179 claims |
| PfizerEliquis | $35 | $110,980155 claims |
| Novo NordiskOzempic | $235 | $92,34987 claims |
| AbbVieCreon, Vraylar | $164 | $63,37434 claims |
| GSKTrelegy Ellipta | $283 | $45,42345 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $211 | $38,35629 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $63 | $35,76964 claims |
| MerckJanuvia | $19 | $29,72922 claims |
| Johnson & JohnsonXarelto | $14 | $12,12622 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $68 | $6,16526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 266 acute care providers in Oklahoma.
Other acute care in Kingfisher
- Karen GregoryOklahoma City$68K
- Pavel BuzadzhiTulsa$26K
- Jerrie MoralesTulsa$15K
- Lisa ArmstrongTulsa$14K
- Ganna StarkeyTulsa$14K
- Katrina PyleOklahoma City$13K
- Deborah PeterOklahoma City$12K
- Jasmine ThompsonTulsa$12K
- Christopher GordonOklahoma City$12K
- Kelli LeekOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.